(Q37273745)

19 August 2017

The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis (English)

1 reference

experimental autoimmune encephalomyelitis

19 August 2017

0 references

author name string

Qing Li

1

1 reference

19 August 2017

Kristine Nacion

2

1 reference

19 August 2017

Hong Bu

3

1 reference

19 August 2017

Feng Lin

4

1 reference

19 August 2017

language of work or name

English

0 references

publication date

16 July 2009

1 reference

The American Journal of Pathology

19 August 2017

1 reference

19 August 2017

175

1 reference

19 August 2017

2

1 reference

19 August 2017

661-667

1 reference

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Lessons for clinical trials from natalizumab in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Mitoxantrone in the treatment of multiple sclerosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

The use of glatiramer acetate in the treatment of multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Animal models for multiple sclerosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Decay-accelerating factor modulates induction of T cell immunity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Targeting complement in therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Diagnosis and management of acute obstetrical DIC.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

The C5a chemoattractant receptor mediates mucosal defence to infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

New synthetic inhibitors of C1r̄, C1 esterase, thrombin, plasmin, kallikrein and trypsin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715286

Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis

3 September 2018

1 reference

12 December 2020

Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis

1 reference

12 December 2020

Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells

1 reference

12 December 2020

IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction

1 reference

12 December 2020

Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis

1 reference

12 December 2020

The allogeneic T and B cell response is strongly dependent on complement components C3 and C4

1 reference

12 December 2020

Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords

1 reference

12 December 2020

Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma

1 reference

12 December 2020

10.2353/AJPATH.2009.081093

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19608865

1 reference